

# Ian Giles

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1875121/publications.pdf>

Version: 2024-02-01

125  
papers

3,426  
citations

147786

31  
h-index

155644

55  
g-index

127  
all docs

127  
docs citations

127  
times ranked

3773  
citing authors

#	ARTICLE	IF	CITATIONS
1	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeedingâ€”Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids: Table 1. <i>Rheumatology</i> , 2016, 55, 1693-1697.	1.9	350
2	Randomized Controlled Trial of Rituximab and Costâ€Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary SjÃ¶gren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017, 69, 1440-1450.	5.6	194
3	ORIGINAL ARTICLE: Antiphospholipid Antibodies Induce a Proâ€Inflammatory Response in First Trimester Trophoblast Via the TLR4/MyD88 Pathway. <i>American Journal of Reproductive Immunology</i> , 2009, 62, 96-111.	1.2	158
4	Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human Î²2-glycoprotein I: Mutation studies including residues R39 to R43. <i>Arthritis and Rheumatism</i> , 2007, 56, 280-290.	6.7	134
5	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeedingâ€”Part II: analgesics and other drugs used in rheumatology practice: Table 1. <i>Rheumatology</i> , 2016, 55, 1698-1702.	1.9	129
6	Brain abnormalities in newly diagnosed neuropsychiatric lupus: Systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. <i>Autoimmunity Reviews</i> , 2015, 14, 153-159.	5.8	106
7	Antibodies to apolipoprotein Aâ€€, highâ€density lipoprotein, and Câ€reactive protein are associated with disease activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010, 62, 845-854.	6.7	100
8	Health-related utility values of patients with primary SjÃ¶gren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1362-1368.	0.9	87
9	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. <i>Blood Reviews</i> , 2020, 39, 100610.	5.7	85
10	The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. <i>Rheumatology</i> , 2011, 50, 1401-1408.	1.9	81
11	The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?. <i>Lupus</i> , 2011, 20, 5-13.	1.6	78
12	Fatigue in primary SjÃ¶gren's syndrome is associated with lower levels of proinflammatory cytokines. <i>RMD Open</i> , 2016, 2, e000282.	3.8	77
13	Symptom-based stratification of patients with primary SjÃ¶gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e85-e94.	3.9	76
14	Does Rheumatoid Arthritis Really Improve During Pregnancy? A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2019, 46, 245-250.	2.0	76
15	Effects of Polyclonal IgG Derived from Patients with Different Clinical Types of the Antiphospholipid Syndrome on Monocyte Signaling Pathways. <i>Journal of Immunology</i> , 2010, 184, 6622-6628.	0.8	67
16	Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of Î²2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. <i>Rheumatology</i> , 2015, 54, 722-727.	1.9	67
17	Measuring IgA Anti-Î²2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. <i>PLoS ONE</i> , 2016, 11, e0156407.	2.5	66
18	Modulation of Trophoblast Angiogenic Factor Secretion by Antiphospholipid Antibodies is Not Reversed by Heparin. <i>American Journal of Reproductive Immunology</i> , 2011, 66, 286-296.	1.2	65

#	ARTICLE	IF	CITATIONS
19	United Kingdom Primary Sjogren's Syndrome Registry--a united effort to tackle an orphan rheumatic disease. <i>Rheumatology</i> , 2011, 50, 32-39.	1.9	64
20	Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. <i>Rheumatology</i> , 2015, 54, 2042-2050.	1.9	61
21	Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1973-1979.	0.9	57
22	Cardiovascular Risk Factors in Women With Primary Sjögren's Syndrome: United Kingdom Primary Sjögren's Syndrome Registry Results. <i>Arthritis Care and Research</i> , 2014, 66, 757-764.	3.4	56
23	Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 911-920.	3.4	54
24	Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce Î²-chemokines. <i>Journal of Experimental Medicine</i> , 2010, 207, 763-776.	8.5	51
25	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome. <i>PLoS ONE</i> , 2015, 10, e0143970.	2.5	45
26	Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. <i>Rheumatology</i> , 2010, 49, 392-394.	1.9	44
27	Association between Systemic Lupus Erythematosus and Periodontitis: A Systematic Review and Meta-analysis. <i>Frontiers in Immunology</i> , 2017, 8, 1295.	4.8	44
28	Antibodies to domain I of Î²-2-glycoprotein I and IgA antiphospholipid antibodies in patients with seronegative antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 317-319.	0.9	42
29	Purified IgG from Patients with Obstetric but not IgG from Non-obstetric Antiphospholipid Syndrome Inhibit Trophoblast Invasion. <i>American Journal of Reproductive Immunology</i> , 2015, 73, 390-401.	1.2	35
30	Fatigue in primary Sjögren's syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. <i>Rheumatology International</i> , 2019, 39, 1867-1873.	3.0	35
31	A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. <i>BMC Biotechnology</i> , 2006, 6, 8.	3.3	33
32	Stratifying management of rheumatic disease for pregnancy and breastfeeding. <i>Nature Reviews Rheumatology</i> , 2019, 15, 391-402.	8.0	33
33	Arginine Residues Are Important in Determining the Binding of Human Monoclonal Antiphospholipid Antibodies to Clinically Relevant Antigens. <i>Journal of Immunology</i> , 2006, 177, 1729-1736.	0.8	30
34	Antibodies to Serine Proteases in the Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2010, 12, 45-52.	4.7	30
35	Examining How Antiphospholipid Antibodies Activate Intracellular Signaling Pathways: A Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 720-736.	3.4	30
36	The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients. <i>Rheumatology</i> , 2012, 51, 1877-1880.	1.9	28

#	ARTICLE	IF	CITATIONS
37	Pregnancy Outcomes in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 128-129.	2.0	27
38	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018, 93, 114-123.	6.5	24
39	IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. <i>Arthritis Research and Therapy</i> , 2015, 17, 26.	3.5	23
40	The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. <i>Arthritis Research</i> , 2005, 7, R47.	2.0	22
41	Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome?. <i>Lupus</i> , 2009, 18, 671-675.	1.6	22
42	Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2013, 109, 72-78.	3.4	22
43	Do the EULAR Sjogren's syndrome outcome measures correlate with health status in primary Sjogren's syndrome?. <i>Rheumatology</i> , 2015, 54, 655-659.	1.9	22
44	Thrombin Binding Predicts the Effects of Sequence Changes in a Human Monoclonal Antiphospholipid Antibody on Its In Vivo Biologic Actions. <i>Journal of Immunology</i> , 2009, 182, 4836-4843.	0.8	19
45	Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome. <i>Blood</i> , 2014, 124, 3808-3816.	1.4	19
46	Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. <i>Rheumatology</i> , 2020, 59, 524-533.	1.9	19
47	Subjective and Objective Measures of Dryness Symptoms in Primary Sjogren's Syndrome: Capturing the Discrepancy. <i>Arthritis Care and Research</i> , 2017, 69, 1714-1723.	3.4	18
48	Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. <i>Cell Death and Disease</i> , 2018, 8, e2549-e2549.	6.3	17
49	Evaluating the conformation of recombinant domain I of Î²2-glycoprotein I and its interaction with human monoclonal antibodies. <i>Molecular Immunology</i> , 2011, 49, 56-63.	2.2	16
50	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. <i>Arthritis Research and Therapy</i> , 2015, 17, 47.	3.5	16
51	Physical activity but not sedentary activity is reduced in primary Sjogren's syndrome. <i>Rheumatology International</i> , 2017, 37, 623-631.	3.0	16
52	Identification of a Novel HIF-1Î±-Î²2 Integrin-NET Axis in Fibrotic Interstitial Lung Disease. <i>Frontiers in Immunology</i> , 2020, 11, 2190.	4.8	16
53	Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. <i>Molecular Immunology</i> , 2004, 40, 745-758.	2.2	15
54	Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis. <i>Arthritis and Rheumatism</i> , 2011, 63, 3512-3521.	6.7	15

#	ARTICLE	IF	CITATIONS
55	The association between IgG and IgM antibodies against cardiolipin, Î²2-glycoprotein I and Domain I of Î²2-glycoprotein I with disease profile in patients with multiple sclerosis. <i>Molecular Immunology</i> , 2016, 75, 161-167.	2.2	14
56	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 2413.	4.8	14
57	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome. <i>RMD Open</i> , 2019, 5, e000885.	3.8	14
58	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. <i>Rheumatology</i> , 2020, 59, 146-152.	1.9	14
59	â€A new dawn of anticoagulation for patients with antiphospholipid syndrome?â€™. <i>Lupus</i> , 2012, 21, 1263-1265.	1.6	13
60	Autoimmune rheumatic disease IgG has differential effects upon neutrophil integrin activation that is modulated by the endothelium. <i>Scientific Reports</i> , 2019, 9, 1283.	3.3	13
61	Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2007, 56, 2392-2401.	6.7	12
62	Going viral in rheumatology: using social media to show that mechanistic research is relevant to patients with lupus and antiphospholipid syndrome. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky003.	0.7	11
63	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. <i>Frontiers in Immunology</i> , 2018, 9, 2244.	4.8	11
64	Real benefits of ultrasound evaluation of hand and foot synovitis for better characterisation of the disease activity in rheumatoid arthritis. <i>European Radiology</i> , 2019, 29, 6345-6354.	4.5	11
65	A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs <i>in utero</i>. <i>Rheumatology</i> , 2022, 61, 3902-3906.	1.9	10
66	How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 525-537.	3.3	9
67	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. <i>Rheumatology</i> , 2015, 55, rev373.	1.9	9
68	Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. <i>Lancet Rheumatology</i> , The, 2021, 3, e9-e10.	3.9	9
69	Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. <i>BMC Biotechnology</i> , 2015, 15, 104.	3.3	8
70	Oxidation of Î²2-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. <i>PLoS ONE</i> , 2017, 12, e0186513.	2.5	8
71	A systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone agonists (GnRHa) in women of child-bearing age with autoimmune rheumatic disease. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 321-333.	3.0	8
72	Mechanisms determining the amelioration of rheumatoid arthritis in pregnancy: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1357-1369.	3.4	8

#	ARTICLE	IF	CITATIONS
73	Poor adherence to guidelines on early management of acute hot swollen joint(s): an evaluation of clinical practice and implications for training. <i>International Journal of Clinical Practice</i> , 2015, 69, 618-622.	1.7	7
74	Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by IgG From Patients With Lupus and/or Antiphospholipid Syndrome. <i>Scientific Reports</i> , 2017, 7, 10788.	3.3	7
75	Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry. <i>Swiss Medical Weekly</i> , 2018, 148, w14588.	1.6	7
76	Fertility and pregnancy in systemic lupus erythematosus. <i>Indian Journal of Rheumatology</i> , 2016, 11, 128.	0.4	6
77	Laboratory Tests for the Antiphospholipid Syndrome. <i>Methods in Molecular Biology</i> , 2014, 1134, 221-235.	0.9	5
78	Prescribing anti-rheumatic drugs in pregnancy and breastfeeding—the British Society for Rheumatology guideline scope. <i>Rheumatology</i> , 2021, 60, 3565-3569.	1.9	5
79	Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2014, 16, R48.	3.5	4
80	Do Antiphospholipid Antibodies Have Direct Pathologic Effects Upon Endometrial and Trophoblast Cells?. <i>Current Rheumatology Reviews</i> , 2009, 5, 83-97.	0.8	4
81	Use of monoclonal antibodies to dissect specificity and pathogenesis of antiphospholipid antibodies. <i>Lupus</i> , 2010, 19, 359-364.	1.6	3
82	Mechanisms of Antiphospholipid Antibody-Mediated Pregnancy Morbidity. , 2017, , 117-143.		3
83	Pathogenesis of Antiphospholipid Antibody Syndrome. , 2019, , 324-337.		3
84	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. <i>Lancet Rheumatology</i> , The, 2020, 2, e735-e736.	3.9	3
85	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis. , 2017, , 77-116.		3
86	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests. , 2017, , 171-187.		3
87	Structure-Function Relationships in Anti-DNA and Anti-Phospholipid Antibodies and their Relevance to the Pathogenesis of Disease. <i>Current Rheumatology Reviews</i> , 2008, 4, 2-11.	0.8	2
88	O26. Does Inflammatory Arthritis Really Improve During Pregnancy? A Systematic Review and Meta-Analysis. <i>Rheumatology</i> , 2014, 53, i40-i40.	1.9	2
89	132 Going viral in rheumatology: a rapid, cost-effective method of obtaining patient opinion about mechanistic research in SLE and APSA. <i>Rheumatology</i> , 2018, 57, .	1.9	2
90	Domain I of Î²2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation. <i>Lupus</i> , 2019, 28, 893-897.	1.6	2

#	ARTICLE	IF	CITATIONS
91	O22â€fEvaluating the impact of COVID-19 on patient access to rheumatology services, medication and future care: a nationwide study of more than 2,000 patients. <i>Rheumatology</i> , 2021, 60, .	1.9	2
92	A Systematic Review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1205-1217.	3.4	2
93	A systematic review of the safety of non-tumour necrosis factor inhibitor and targeted synthetic drugs in rheumatic disease in pregnancy. <i>Clinical Medicine</i> , 2020, 20, s98-s98.	1.9	2
94	138.â€fHow Acceptable is Ovarian Protection to Woman of Childbearing Age Treated with Cyclophosphamide: Experience at a Single Centre. <i>Rheumatology</i> , 2015, , .	1.9	1
95	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017, 19, 287.	3.5	1
96	O63â€fReal-life benefits of ultrasound evaluation of hand and foot synovitis and lack of correlation with DAS-28 in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, .	1.9	1
97	P116â€fA systematic review of the safety of non-tumour necrosis factor inhibitor and targeted synthetic drugs in rheumatic disease in pregnancy. <i>Rheumatology</i> , 2020, 59, .	1.9	1
98	P202â€fAdministering live vaccines to infants exposed to biologic and targeted synthetic DMARDs in-utero for maternal treatment of rheumatic disease: a systematic review of the literature. <i>Rheumatology</i> , 2021, 60, .	1.9	1
99	Update on Use of Biologic and Targeted Synthetic Drugs in Pregnancy. , 2020, , 77-92.		1
100	Wrist joint aspiration. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2012, 73, C2-C4.	0.5	0
101	O59.â€fThe Cellular Effects of Anti-Factor Xa Antibodies Isolated from Patients with Antiphospholipid Syndrome are Inhibited by Factor Xa Inhibitors, Hydroxychloroquine and Fluvastatin. <i>Rheumatology</i> , 2014, 53, i56-i56.	1.9	0
102	144.â€fTo Aspirate or Not to Aspirate: A Trainee Doctor's Dilemma. <i>Rheumatology</i> , 2014, 53, i114-i114.	1.9	0
103	324.â€fFactor-Xa-Reactive Antibodies in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome Have Differential Effects on Coagulation Assays. <i>Rheumatology</i> , 2014, 53, i181-i181.	1.9	0
104	139â€fA Single-Centre Experience of the Issues Discussed During Pre-Pregnancy Counselling of Patients with Inflammatory Rheumatic Disease. <i>Rheumatology</i> , 0, , .	1.9	0
105	236.â€fHYPOXIA MODULATES NEUTROPHIL INTEGRIN EXPRESSION AND ACTIVATION. <i>Rheumatology</i> , 2017, 56, .	1.9	0
106	239.â€fPEGYLATED DOMAIN I OF BETA-2-GLYCOPROTEIN I PREVENTS THROMBOSIS IN A MOUSE MODEL. <i>Rheumatology</i> , 2017, 56, .	1.9	0
107	240.â€fAUTOIMMUNE RHEUMATIC DISEASE IMMUNOGLOBULIN G DIFFERENTIALLY REGULATES NEUTROPHIL INTEGRIN ACTIVATION AND NEUTROPHIL ACTIVATION. <i>Rheumatology</i> , 2017, 56, .	1.9	0
108	126â€fCross sectional validation of BILAG2004-Pregnancy Index. <i>Rheumatology</i> , 2018, 57, .	1.9	0



#	ARTICLE	IF	CITATIONS
109	252â€fExamining the modulatory effects of anti-serine protease antibodies upon factor Xa, thrombin and complement interactions. Rheumatology, 2018, 57, .	1.9	0
110	O21â€fBILAG2004-Pregnancy index is sensitive to change. Rheumatology, 2018, 57, .	1.9	0
111	O37â€fA systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone analogues in women of child-bearing age with autoimmune rheumatic disease. Rheumatology, 2019, 58, .	1.9	0
112	O22â€fBoth Domain I and PEGylated Domain I of Beta-2-Glycoprotein I (Î²2GPI) are capable of inhibiting IgA APS antibody binding. Rheumatology, 2019, 58, .	1.9	0
113	O90â€fMechanisms determining disease activity of rheumatoid arthritis in pregnancy: a systematic review. Rheumatology, 2019, 58, .	1.9	0
114	I065â€fConsidering fertility: do women (or men) with rheumatic disease have fewer children?. Rheumatology, 2019, 58, .	1.9	0
115	O19â€fModulation of monocyte autophagy as a therapeutic target in antiphospholipid syndrome. Rheumatology, 2019, 58, .	1.9	0
116	OP0044â€f...A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE GONADOTOXIC EFFECTS OF CYCLOPHOSPHAMIDE AND BENEFITS OF GONADOTROPIN RELEASING HORMONE ANALOGUES IN WOMEN OF CHILD-BEARING AGE WITH AUTOIMMUNE RHEUMATIC DISEASE. , 2019, , .		0
117	EP31â€fMusculoskeletal ultrasound of rheumatoid arthritis pregnancy: a single centre experience. Rheumatology, 2020, 59, .	1.9	0
118	P172â€fAnti-domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development. Rheumatology, 2020, 59, .	1.9	0
119	P31â€f...Anti-domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development. , 2020, , .		0
120	Ensuring high standards of British Society for Rheumatology clinical guidelines: reflections from the coalface. Rheumatology, 2021, 60, 2497-2499.	1.9	0
121	P065â€fThe road to recovery: developing a new service for urgent face-to-face rheumatology outpatient appointments during the COVID-19 pandemic: a single centre experience. Rheumatology, 2021, 60, .	1.9	0
122	A career in rheumatology. BMJ: British Medical Journal, 2003, 326, 157Sa-157.	2.3	0
123	Play attention! Therapeutic aspects to play in delirium prevention and management. Wellcome Open Research, 2020, 5, 277.	1.8	0
124	Haemophagocytic lymphohistiocytosis in pregnancy. Clinical Medicine, 2021, 21, e682.2-e683.	1.9	0
125	Postpartum venous thromboprophylaxis needs to be stratified in inflammatory diseases. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, , .	2.3	0